Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates

Item

http://www.wikidata.org/entity/Q41902281

Q41902281

about

Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: Mechanism of drug recognition and resistance Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting Association of first-line and second-line antiretroviral therapy adherence.Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria.Highly resistant HIV-1 proteases and strategies for their inhibition.Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.Second generation HIV protease inhibitors against resistant virus.2014 Update of the drug resistance mutations in HIV-1 Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.HIV-2 Protease resistance defined in yeast cells.Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.

P2860

Q27650863-3E4C359F-0FC3-4FA7-AE39-FEE227AA55E5 Q27678735-005EC47A-3365-4041-A385-BF91DC7C0D60 Q28481468-D8DE36FE-5181-47B4-92A5-D53250AED4AD Q33750994-5A94A052-28B5-4ACC-A7B8-98FCDEA7326D Q34409020-C72930EF-4223-421E-BA9B-0E26893621B9 Q34730950-18C4B989-A838-4736-8218-BBFE036E58A8 Q34778123-FB7C2919-C63F-4E2E-9F47-7D10A7BADEED Q34801978-EE8FFCE8-B331-403C-8163-238BD71ECDEE Q34998736-9D466ED1-A48C-4091-9AC1-BAED37AA7E97 Q35907004-20C1BD83-8921-4436-B42A-2E2588DF9021 Q36094935-36BFAA66-7898-4D13-910A-B495F92AAEEC Q36094944-7B0DBC4F-E6CA-45D1-A488-63625EB29BE7 Q36222013-3C37171D-B53F-4213-996F-DF8D02E40718 Q36424925-5EC4EA4E-FA4C-4380-9185-FD00EA340FC3 Q36723780-7DAD9A2D-7F23-43EC-84BA-BAA3FE5E534A Q36727919-AFA6CD27-AB96-411D-B4B0-181C974410EF Q37256366-821E3F32-15AD-4493-AA2E-445EFD49FA8B Q38089895-DA5DFB3D-D996-4358-A0A0-0E50404E671E Q39498339-64B49D30-2A1F-41B9-A548-653477BA5584 Q43057951-DAF8F9C7-077B-433C-BF4D-7C2238F0375C Q43249256-7D9C6F59-72EF-41E9-8594-9E92667D19A4 Q49711913-CBE04921-2641-4B09-A8E8-2AE301CA074F

P2860

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates

Item

http://www.wikidata.org/entity/Q41902281

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Selection of resistance in pro ...... tterns and baseline correlates

@en

type

Item

label

Selection of resistance in pro ...... tterns and baseline correlates

@en

prefLabel

Selection of resistance in pro ...... tterns and baseline correlates

@en

P1476

Selection of resistance in pro ...... tterns and baseline correlates

@en

P2093

Akhteruzzaman Molla

http://www.w3.org/2001/XMLSchema#string

Dale J Kempf

http://www.w3.org/2001/XMLSchema#string

Hongmei Mo

http://www.w3.org/2001/XMLSchema#string

Kathryn King

http://www.w3.org/2001/XMLSchema#string

Martin S King

http://www.w3.org/2001/XMLSchema#string

Scott Brun

http://www.w3.org/2001/XMLSchema#string

P2860

X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease

In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.

Clinically validated genotype analysis: guiding principles and statistical concerns.

A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.

P304

3329-3338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.79.6.3329-3338.2005

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Akhteruzzaman Molla

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15731227

http://www.w3.org/2001/XMLSchema#string

P932

1075714

http://www.w3.org/2001/XMLSchema#string

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates

about

P2860

P2860

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932